Lozza L, Merola M, Fontanelli R, Stefanon B, Seregni E, Bombardieri E, De Palo G
Division of Radiotherapy A, Istituto Nazionale Tumori, Milan, Italy.
Anticancer Res. 1997 Jan-Feb;17(1B):525-9.
The clinical value of SCC levels has been evaluated in four groups of women affected by cervical carcinoma. Among the 116 newly diagnosed patients, the SCC pretreatment level was elevated in 57% of cases and was strictly correlated with clinical stage (Ib to IV: p = < 0.01) and histotype (squamous cell carcinoma versus others: p = 0.0005). No significant difference was found in relation to nodal status. For the 28 patients submitted to neoadjuvant chemotherapy clinical response was correlated with the change in serum SCC level: stable or rising serum level indicated that the disease was unchanged or progressive, respectively. In the group of 48 patients affected by recurrent carcinoma, a raised SCC level was found in 71% of cases, with a lead time ranging from 0 to 12 months. No identification of the site of recurrence could be extrapolated from the value of SCC. As to the 108 regularly monitored patients, no significant difference in the risk to develop recurrence was shown for patients with a raised SCC level at the time of primary diagnosis (NED) versus relapsed: p = > 0.05).
已在四组宫颈癌女性患者中评估了鳞状细胞癌（SCC）水平的临床价值。在116例新诊断患者中，57%的病例SCC治疗前水平升高，且与临床分期（Ib至IV期：p = <0.01）和组织类型（鳞状细胞癌与其他类型：p = 0.0005）密切相关。在淋巴结状态方面未发现显著差异。对于28例接受新辅助化疗的患者，临床反应与血清SCC水平的变化相关：血清水平稳定或升高分别表明疾病无变化或进展。在48例复发性癌患者组中，71%的病例SCC水平升高，提前期为0至12个月。无法从SCC值推断出复发部位。对于108例定期监测的患者，在初次诊断（无疾病证据）时SCC水平升高的患者与复发患者相比，发生复发的风险无显著差异（p = >0.05）。
